96 related articles for article (PubMed ID: 11496328)
21. Enhanced tumor binding using immunohistochemical analyses by second generation anti-tumor-associated glycoprotein 72 monoclonal antibodies versus monoclonal antibody B72.3 in human tissue.
Molinolo A; Simpson JF; Thor A; Schlom J
Cancer Res; 1990 Feb; 50(4):1291-8. PubMed ID: 2297774
[TBL] [Abstract][Full Text] [Related]
22. Evidence of surfactant protein A and D expression decrement and their localizations in human prostate adenocarcinomas.
Kankavi O; Baykara M; Eren Karanis MI; Bassorgun CI; Ergin H; Ciftcioglu MA
Ren Fail; 2014 Mar; 36(2):258-65. PubMed ID: 24168624
[TBL] [Abstract][Full Text] [Related]
23. Expression of p160erbB-3 and p185erbB-2 in prostatic intraepithelial neoplasia and prostatic adenocarcinoma.
Myers RB; Srivastava S; Oelschlager DK; Grizzle WE
J Natl Cancer Inst; 1994 Aug; 86(15):1140-5. PubMed ID: 7913137
[TBL] [Abstract][Full Text] [Related]
24. The prognostic role of tumor associated glycoprotein 72 (TAG-72) in stage II and III colorectal adenocarcinoma.
Cho J; Kim KM; Kim HC; Lee WY; Kang WK; Park YS; Ha SY
Pathol Res Pract; 2019 Jan; 215(1):171-176. PubMed ID: 30466765
[TBL] [Abstract][Full Text] [Related]
25. Ep-Cam levels in prostatic adenocarcinoma and prostatic intraepithelial neoplasia.
Poczatek RB; Myers RB; Manne U; Oelschlager DK; Weiss HL; Bostwick DG; Grizzle WE
J Urol; 1999 Oct; 162(4):1462-6. PubMed ID: 10492238
[TBL] [Abstract][Full Text] [Related]
26. In vitro and ex vivo expression of nucleolar proteins B23 and p120 in benign and malignant epithelial lesions of the prostate.
Bocker T; Bittinger A; Wieland W; Buettner R; Fauser G; Hofstaedter F; Rüschoff J
Mod Pathol; 1995 Apr; 8(3):226-31. PubMed ID: 7542384
[TBL] [Abstract][Full Text] [Related]
27. Expression of TAG-72 in ovarian cancer and its correlation with tumor stage and patient prognosis.
Ponnusamy MP; Venkatraman G; Singh AP; Chauhan SC; Johansson SL; Jain M; Smith L; Davis JS; Remmenga SW; Batra SK
Cancer Lett; 2007 Jun; 251(2):247-57. PubMed ID: 17210225
[TBL] [Abstract][Full Text] [Related]
28. De novo expression of CD44 in prostate carcinoma is correlated with systemic dissemination of prostate cancer.
Paradis V; Eschwège P; Loric S; Dumas F; Ba N; Benoît G; Jardin A; Bedossa P
J Clin Pathol; 1998 Nov; 51(11):798-802. PubMed ID: 10193318
[TBL] [Abstract][Full Text] [Related]
29. Immunocytochemical evaluation of human prostatic carcinomas for carcinoembryonic antigen, nonspecific cross-reacting antigen, beta-chorionic gonadotrophin, and prostate-specific antigen.
Purnell DM; Heatfield BM; Trump BF
Cancer Res; 1984 Jan; 44(1):285-92. PubMed ID: 6197163
[TBL] [Abstract][Full Text] [Related]
30. Use of a monoclonal antibody (B72.3) as a novel immunohistochemical adjunct for the diagnosis of carcinomas in fine needle aspiration biopsy specimens.
Johnston WW; Szpak CA; Lottich SC; Thor A; Schlom J
Hum Pathol; 1986 May; 17(5):501-13. PubMed ID: 2422108
[TBL] [Abstract][Full Text] [Related]
31. Comparative dual label study of first and second generation antitumor-associated glycoprotein-72 monoclonal antibodies in colorectal cancer patients.
Gallinger S; Reilly RM; Kirsh JC; Odze RD; Schmocker BJ; Hay K; Polihronis J; Damani MT; Shpitz B; Stern HS
Cancer Res; 1993 Jan; 53(2):271-8. PubMed ID: 8417820
[TBL] [Abstract][Full Text] [Related]
32. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature.
Chang SS; Reuter VE; Heston WD; Bander NH; Grauer LS; Gaudin PB
Cancer Res; 1999 Jul; 59(13):3192-8. PubMed ID: 10397265
[TBL] [Abstract][Full Text] [Related]
33. Adenocarcinoma of the canine prostate: immunohistochemical examination for secretory antigens.
McEntee M; Isaacs W; Smith C
Prostate; 1987; 11(2):163-70. PubMed ID: 2444955
[TBL] [Abstract][Full Text] [Related]
34. Heat shock protein expression independently predicts clinical outcome in prostate cancer.
Cornford PA; Dodson AR; Parsons KF; Desmond AD; Woolfenden A; Fordham M; Neoptolemos JP; Ke Y; Foster CS
Cancer Res; 2000 Dec; 60(24):7099-105. PubMed ID: 11156417
[TBL] [Abstract][Full Text] [Related]
35. Immunohistochemical evaluation of canine carcinomas with monoclonal antibody B72.3.
Clemo FA; DeNicola DB; Delaney LJ
Vet Pathol; 1993 Mar; 30(2):140-5. PubMed ID: 8470336
[TBL] [Abstract][Full Text] [Related]
36. Expression of Das-1 in primary lung adenocarcinomas represents reactivation of an oncofetal pulmonary antigen.
Deshpande CG; Shah RN; Yeldandi A; Papreddy K; Badve S
Pathobiology; 2002-2003; 70(6):343-7. PubMed ID: 12865630
[TBL] [Abstract][Full Text] [Related]
37. Reduced 15-lipoxygenase-2 immunostaining in prostate adenocarcinoma: correlation with grade and expression in high-grade prostatic intraepithelial neoplasia.
Jack GS; Brash AR; Olson SJ; Manning S; Coffey CS; Smith JA; Shappell SB
Hum Pathol; 2000 Sep; 31(9):1146-54. PubMed ID: 11014584
[TBL] [Abstract][Full Text] [Related]
38. Dunning rat prostate tumors and cultured cell lines fail to express human prostate carcinoma-associated antigens.
Newhall KR; Isaacs JT; Wright GL
Prostate; 1990; 17(4):317-25. PubMed ID: 1701250
[TBL] [Abstract][Full Text] [Related]
39. The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate.
Sheridan T; Herawi M; Epstein JI; Illei PB
Am J Surg Pathol; 2007 Sep; 31(9):1351-5. PubMed ID: 17721190
[TBL] [Abstract][Full Text] [Related]
40. Concordant induction of 15-lipoxygenase-1 and mutant p53 expression in human prostate adenocarcinoma: correlation with Gleason staging.
Kelavkar UP; Cohen C; Kamitani H; Eling TE; Badr KF
Carcinogenesis; 2000 Oct; 21(10):1777-87. PubMed ID: 11023533
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
